Kodiak Sciences (KOD) Return on Capital Employed (2018 - 2026)
Kodiak Sciences (KOD) posted Return on Capital Employed of 84.2% for Q1 2026, up 14.04% on a QoQ basis from 97.96% in Q4 2025, and down 1429.0% year-over-year from 6.34% in Q1 2025.
Kodiak Sciences (KOD) Return on Capital Employed (2018 - 2026) Analysis & Trends
Kodiak Sciences' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 84.2% for Q1 2026.
- Quarterly Return on Capital Employed fell 1429.0% year-over-year to 84.2% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 84.2% (down 1429.0% YoY) and the FY2025 annual result came in at 78.65%, down 2972.0% from the prior year.
- Return on Capital Employed was 84.2% for Q1 2026 at Kodiak Sciences, up from 97.96% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 38.99% in Q1 2022 and bottomed at 114.44% in Q3 2025.
- A 5-year average of 64.43% and a median of 57.56% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 450 bps — and 2025, when it plunged 5824 bps.
- Kodiak Sciences' Return on Capital Employed stood at 53.11% in 2022, then declined by 11 bps to 58.78% in 2023, then gained by 3 bps to 56.87% in 2024, then plunged by 72 bps to 97.96% in 2025, then climbed by 14 bps to 84.2% in 2026.
- Business Quant data shows KOD's Return on Capital Employed at 84.2% in Q1 2026, 97.96% in Q4 2025, and 114.44% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Kodiak Sciences | 2.54 Bn | 2.54 Bn | - | -84.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.20% |
| Dec 31, 2025 | -97.96% |
| Sep 30, 2025 | -114.44% |
| Jun 30, 2025 | -84.20% |
| Mar 31, 2025 | -69.92% |
| Dec 31, 2024 | -56.87% |
| Sep 30, 2024 | -56.20% |
| Jun 30, 2024 | -53.38% |
| Mar 31, 2024 | -57.56% |
| Dec 31, 2023 | -58.78% |
| Sep 30, 2023 | -57.85% |
| Jun 30, 2023 | -57.88% |
| Mar 31, 2023 | -54.78% |
| Dec 31, 2022 | -53.11% |
| Sep 30, 2022 | -52.43% |
| Jun 30, 2022 | -46.69% |
| Mar 31, 2022 | -38.99% |
| Dec 31, 2021 | -30.82% |
| Sep 30, 2021 | -23.91% |
| Jun 30, 2021 | -19.50% |